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Abstract
Hereditary spastic paraplegia (HSP) is a group of heterogeneous inherited degenerative disorders characterized by lower
limb spasticity. Fifty percent of HSP patients remain yet genetically undiagnosed. The 100,000 Genomes Project (100KGP)
is a large UK-wide initiative to provide genetic diagnosis to previously undiagnosed patients and families with rare
conditions. Over 400 HSP families were recruited to the 100KGP. In order to obtain genetic diagnoses, gene-based burden
testing was carried out for rare, predicted pathogenic variants using candidate variants from the Exomiser analysis of the
genome sequencing data. A significant gene-disease association was identified for UBAP1 and HSP. Three protein truncating
variants were identified in 13 patients from 7 families. All patients presented with juvenile form of pure HSP, with median
age at onset 10 years, showing autosomal dominant inheritance or de novo occurrence. Additional clinical features included
parkinsonism and learning difficulties, but their association with UBAP1 needs to be established.
Introduction
Hereditary spastic paraplegia (HSP) represents a wide
spectrum of rare inherited neurodegenerative conditions,
typically characterized by progressive limb spasticity. HSP
is traditionally classified into pure and complicated forms,
depending on the presence of additional clinical features,
such as cognitive decline, cerebellar ataxia, peripheral
neuropathy, or parkinsonism. To date, more than 80 genes
have been associated with HSP under various modes of
inheritance, including autosomal recessive, autosomal
dominant (AD), or X-linked [1].
Recent advances in molecular analysis techniques have
led to the identification of new genetic loci associated with
HSP. Yet, for up to 70% of cases clinically diagnosed as
HSP the genetic cause remains unknown [2].
The 100,000 Genomes Project (100KGP) was established
to deliver advanced genomic testing for NHS patients with
rare disease and cancer. One of the aims of the rare disease
arm of the project was to make molecular diagnoses and novel
gene discoveries through whole genome sequencing. Over
60,000 participants with genetically undiagnosed rare disease
have been recruited [3], including over 400 HSP families.
Here, we describe 13 patients from 7 families with HSP
recruited to the 100KGP, who carry 3 truncating variants in
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UBAP1, a newly identified gene that causes pure forms of
juvenile HSP [4]. Variant interpretation analysis had been
initially carried out via the 100KGP automated pipeline in
known HSP genes [5], and failed to identify a genetic diag-
nosis in all families. An ongoing re-analysis of the data in the
research environment using gene-based burden testing for rare,
predicted damaging variants allowed the rapid identification of
the three pathogenic UBAP1 variants in seven families.
Materials and methods
Patients
Following ethical approval (14/EE/1112), consenting par-
ticipants were recruited to the 100KGP cohort. Standardized
baseline clinical data were recorded at the time of recruit-
ment using the Human Phenotyping Ontology, according to
the HSP data model (Supplementary information). Further,
additional information was collected retrospectively by
contacting the recruiting clinician for each patient (sum-
marized in Table 1). Patients had been previously tested
negative for single nucleotide variants, small deletions/
insertions and CNVs in genes from the PanelApp [5]
curated virtual gene panel for HSP. CNV calls were gen-
erated by Genomics England using Manta and Canvas
software (Illumina) and processed using custom R scripts to
detect CNVs overlapping the SPAST gene [5]. No likely
pathogenic variants were identified.
Gene-based burden testing
A statistical analysis framework was developed to detect
enrichment of rare, predicted pathogenic variants in novel
genes for specific diseases. The analysis was run on all rare,
coding variants that segregated with disease as expected for
each possible mode of inheritance (minor allele frequencies,
MAF < 0.1% dominant, <1% recessive), identified from
Exomiser [6, 7] analysis of each case’s whole genome data.
The following case-control association analysis framework
was used: “case” sets were defined as all 100KGP probands
recruited under HSP, while corresponding “control” sets
were all recruited 100KGP probands except those recruited
under a neurological disorder. We tested for enrichment of
rare variants using Fisher’s exact test under four scenarios:
(1) rare, predicted pathogenic variants (Exomiser variant
score > 0.8 corresponding to rare variants that are predicted
to be pathogenic by in silico prediction tools REVEL [8]
and/or MVP [9]), (2) rare variants in a constrained coding
region [10], (3) rare, predicted loss of function (LoF) var-
iants, (4) rare, de novo variants. For the latter, only trios or
larger families where de novo calling was possible were
considered. The Benjamini and Hochberg method was used
to correct for multiple testing; an overall false discovery rate
adjusted q value threshold of 0.10 was used for claiming
significant gene-disease associations.
All variants described in this study have been submitted
to ClinVar.
Results
In the context of an ongoing gene-based burden analysis of
the rare disease component of the 100KGP data, a significant
gene-disease association was identified for UBAP1 and HSP.
A significant excess of LoF variants was observed in 5 out of
417 HSP cases compared to 16,449 non-neurological
100KGP probands used as controls (odds ratio, OR= 66.5;
q value= 0.002). Through further inspection of newly
available 100KGP data and other neurological probands that
were excluded from the case-control analysis dataset, we
identified two additional patients with spastic paraplegia and
UBAP1 truncating variants. One of these patients had been
recruited under HSP diagnosis and the other as familial Par-
kinson’s disease (PD), but was also affected by HSP.
In total, seven families carrying three different truncating
variants in UBAP1 were identified in the 100KGP data
(Table 1, ClinVar SUB7456898). Families 1 and 2 were
consistent with de novo occurrence of HSP (Fig. 1a), while
the pedigrees of families 3–7 suggested an AD pattern of
inheritance (Fig. 1a) that was confirmed by segregation
analysis in family 5 (Fig. 1b). The identified variants
included: c.426_427del; p.(Lys143SerfsTer15) in two
families, c.535G > T; p.(Glu179Ter) in four families and
c.373C > T; p.(Gln125Ter) in one family (NM_016525.4;
NP_057609.2) (Fig. 1a).
The median age at onset was 10 years (interquartile range
9–11 years). In most cases the onset occurred during
childhood, with some individuals having a later age at
onset, including early adulthood. The latest age at onset was
30 years (Table 1).
Overall, clinical history and examination of the 13
individuals were consistent with uncomplicated HSP phe-
notype. The first symptoms included difficulties with run-
ning and walking, with frequent falls and leg scissoring also
reported. Disease course was similar in all families, with
slowly progressive lower limb spasticity and weakness,
except proband of family 1, who progressed over 2–3 years
to wheelchair use. Additional symptoms included learning
difficulties in family 5, reduced light touch in the lower limb
distally and upper limb areflexia in one of the affected
members of family 6, although no results of nerve con-
duction studies were available. Intrafamilial heterogeneity
was observed, with a milder phenotype usually associated
with a later age of onset. At the time of examination, the
most frequent signs included lower limb weakness, extensor


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Identification of UBAP1 mutations in juvenile hereditary spastic paraplegia in the 100,000 Genomes. . . 1765
plantars and brisk reflexes of the lower limbs. Only the
proband of family 4 presented brisk upper limb reflexes,
while none of the individuals of our cohort had spasticity or
weakness of the upper limbs. Bladder dysfunction, mainly
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Fig. 1 Pedigrees, DNA, RNA and protein analysis of UBAP1.
a Pedigrees, b Sanger Sequencing, c Western Blot, d RNA. a Pedigrees
of families reported in this study. Squares represent males, circles
represent females, shaded shapes represent individuals with HSP, and
unshaded shapes represent individuals without HSP. b Electropherograms
of Sanger sequencing performed for the validation of variants identified in
families 3, 4, and 5. c Western Blot analysis for the proband of family 4
(p.Gln125Ter/WT) and two healthy controls (WT/WT), showing reduced
expression of normal size ubiquitin-associated protein 1 (UBAP1) and the
presence of a smaller additional band in the proband, indicating the
presence of truncated protein. Loading control with β-actin.was performed
to confirm that the same amount of the total protein was loaded for all
three samples. d Gel electrophoresis of PCR products amplified from
cDNA synthesized from RNA of the proband of family 4 (c.373C >T)
and a healthy control, showing the presence of amplicons of target
sequence in both samples. Sanger sequencing of the same PCR products
confirm the result as well as the presence of the variant in the proband, as
shown by the respective electropherograms. WT wild type; KDa kilo-
dalton; bp base pairs.
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Interestingly, in two of the families an extrapyramidal
syndrome consistent with typical Parkinson Disease pre-
sented later on in the disease course. The proband of family
2 was diagnosed with levodopa-responsive PD in his mid-
1950s, with predominantly left-sided rest tremor, bradyki-
nesia and cogwheel rigidity particularly in the upper limb,
facial hypomimia, and normal eye movements. The
DaTscan was reported abnormal for bilaterally reduced
uptake of the tracer in the striatum. The father of the pro-
band of family 3, who was also affected by HSP, was
reported to have PD with onset in early 1970s. Each family
carried a different pathogenic variant. The size of this
analysis does not allow to correlate the presence of par-
kinsonism with the identified pathogenic variants in
UBAP1.
A Western Blot for the proband of family 4, carrying a
heterozygous c.373C > T; p.Gln125Ter variant, revealed the
presence of truncated protein along with reduced amount of
normal size protein (Fig. 1c). PCR of c.DNA, synthesized
from RNA isolated from the same individual, showed that
mRNA escapes nonsense mediated decay (Fig. 1d), as
previously reported [4].
Discussion
Here, we describe the genetic and clinical features of a
cohort of UK HSP patients due to UBAP1 protein trun-
cating variants. The 100KGP is a research project to
implement WGS in a national healthcare system. Patient
with a clinical diagnosis of HSP were recruited from local
hospitals in England. In most cases, the relevant HSP genes
were sequenced prior to recruitment. This dataset represents
one of the largest HSP cohort with WGS data from a single
country. In this dataset the prevalence of UBAP1 in HSP is
1.7% (7 families out of 417).
Ubiquitin-associated protein 1 (encoded by UBAP1)
constitutes a subunit of mammalian endosomal sorting
complex required for transport I (ESCRT-I) and is involved
in endosomal dynamics in neurons. Furthermore, it is
involved in proteasomal degradation of ubiquitinated pro-
teins. Both cellular pathways have been involved in HSP
and our study further confirms the importance of such
pathways in this disease [11].
While we were conducting this study, truncating UBAP1
variants were reported in HSP families of diverse geographic
origin, including the three variants we are reporting in this
study [4, 12–14]. Thus far, and including our study, 30
families with AD HSP have been reported (Supplementary
Table 1). The majority of the patients present with a pure form
of juvenile-onset HSP. Of all cases reported, the average age
at onset of symptoms was 9 years (interquartile range 7–11
years). Adult onset has been reported in two cases only (onset
at age 30 and 61, respectively). Although a pure HSP phe-
notype has been reported in most families, two of the pre-
viously reported families additionally presented with
cerebellar symptoms, while two of the families reported in
this study presented with symptoms typical of an extra-
pyramidal disorder, this was later on in the disease course.
While most families present with positive family history, de
novo occurrence is reported in seven families. Incomplete
penetrance has been described in three families.
In total, 14 different truncating variants have been reported
so far. All but one of these variants occur within exon 4 of
UBAP1 (Fig. 2). The most frequent mutation identified so far
by all studies is the p.(Lys143Serfs*15), reported in 11
families out of 30 across different populations. In the current
study, representing HSP in the British population, the most
Fig. 2 Schematic representation of UBAP1 with all variants
reported in this study and previously. The table indicates the number
of families carrying each variant. Each circle represents one family.
Shaded circles represent positive family history, unshaded circles
represent de novo occurrence, and half-shaded circles indicate unknown
family history. Exons are numbered like in Fard et al. 2019 [4].
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frequent mutation is p.(Glu179Ter), only previously described
in one family in the Japanese population [13].
Our study provides further evidence that UBAP1 causes
mostly pure forms of AD HSP. Among the known genes
that cause pure forms of HSP, with 30 families described so
far, UBAP1 is a common cause of AD juvenile pure HSP.
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